ERBB2 and breast cancer: Further analysis showed that the ER/PR positive patients with lower Linc01315 expression displayed longer DFS (P=0.013; P=0.019) and OS (P=0.004; P=0.006) (Figures 3A, B; Figures 4A, B), while OS and DFS analysis in HER2+ breast cancer and triple negative breast cancer showed no significant difference (Supplementary Figure 3).